Difference between revisions of "Ravulizumab (Ultomiris)"
(Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/complement-c5-inhibitor-alxn1210 NCI Drug Dictionary]: A lon...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
Line 22: | Line 22: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | + | ||
[[Category:Anti-C5 antibodies]] | [[Category:Anti-C5 antibodies]] | ||
Revision as of 19:32, 27 February 2020
General information
Class/mechanism from the NCI Drug Dictionary: A longer-acting antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, ravulizumab-cwvz binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). Compared to other anti-C5 antibodies, ALXN1210 is longer-acting and allows for monthly dosing.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 12/21/2018: Initial approval for adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Also known as
- Code name: ALXN1210
- Generic name: ravulizumab-cwvz
- Brand name: Ultomiris